CRISPR Therapeutics AG — Revenue by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/9d1fe912-bd92-40c8-8d49-60eb7e9d2880/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $3.5M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-048957 |
| FY 2024 | $37.3M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-017899 |
| FY 2023 | $371.2M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-017571 |
| FY 2022 | $1.2M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-003441 |
| FY 2021 | $915.0M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-001282 |
| FY 2020 | $719.0k | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-006074 |
| FY 2019 | $289.6M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-006074 |
| FY 2018 | $3.1M | 2018-01-01 – 2018-12-31 | evidence 0001564590-21-006074 |
| FY 2017 | $41.0M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004920 |
| FY 2016 | $5.2M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003977 |
| FY 2015 | $247.0k | 2015-01-01 – 2015-12-31 | evidence 0001564590-17-003977 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CRISPR Therapeutics AG — all facts · Net Income · Operating Income